This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
TFF Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, has announced a collaboration with Aptar Pharma, a global leader in drug delivery and active material science solutions and services, aimed at developing and testing the administration of dry powder vaccines utilizing TFF Pharmaceutical’s Thin Film Freezing technology and Aptar Pharma’s intranasal Unidose (UDS) Powder Nasal Spray System.
The development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous, or intramuscular-based delivery. The nasal passageway is very often the first point of entry for respiratory pathogens, and if the pathogen can be halted in the nasal passages, the spread of infection is likely to be significantly curtailed, leading to an improved prognosis. In addition, the direct immunization of nasal mucosa may promote both systemic and mucosal immunity. Mucosal immunity may be a key to preventing viral shedding and disease transmission.
Furthermore, self-administration of a “needle-free” vaccine provides pain-free administration to the patient, results in less medical waste by avoiding syringe disposal, eliminates extreme cold storage requirement from the supply chain, and simplifies global distribution. These aspects of nasal delivery could expand vaccine availability to larger populations in regions and countries with limited refrigeration infrastructure.
During the Vaccines Summit-2022, Aptar Pharma presented research findings from its collaboration with TFF Pharmaceuticals. The presentation highlighted data related to nasal deposition of a dry powder vaccine, physical characteristics of the administered formulation, the integrity and activity testing of the dry powder vaccine after administration, and the emitted particle size. The amount of dry powder delivered to the targeted region of the nasal cavity was also presented. Aptar Pharma will present additional data on these efforts at the World Vaccine & Immunotherapy Congress, which will be held in San Diego, CA from November 28 to December 1, 2022.
“We are very excited to partner with Aptar Pharma to test our Thin Film Freezing formulation with their unique intranasal device,” says Glenn Mattes, president & CEO of TFF Pharmaceuticals. “By combining our collective and proprietary expertise in drug development, device engineering, and formulation technologies, we believe this collaboration has the potential to create ground-breaking advancements in the field of drug delivery. Intranasal dry powder vaccines could be a true game changer for people around the world.”
“The nasal vaccine formulation developed using TFF Pharmaceutical’s technology combines the antigen and adjuvant into one ready-to-use device,” says Dr. Julie D. Suman, vice president, scientific affairs at Aptar Pharma. “This eliminates the need for combining separate vials, saves time, and reduces human error and medical waste.”
The results of the feasibility testing will be published by Aptar Pharma, The University of Texas at Austin (UT), and TFF Pharmaceuticals in the coming months. Aptar, UT, and TFF are preparing to summarize the results of the initial intranasal vaccine feasibility testing in a pre-print publication to be followed by a peer-reviewed publication in the coming months.
